Themis Medicare Ltd. — Interim / Quarterly Report 2022

Nov 12, 2021

TML CS BDM—40/ 2021—22 12'h November. 2021

BSE Limited. National Stock Exchange of India Ltd. P J Towers. Dalal Street. "Exchange Plaza" Mumbai-400001 Bandra — Kurla Complex: Bandra —— East,Mumbai— 400 0551

Dear Sir/Madam.

Sub: Outcome of the Board Meeting

MeetingCommencementtime	:	11:00AM
MeetingConclusmnTime	:	01:15PM

The Board of Directors at its meeting held today, considered and approved the followrng matters

• 1. Approved the Unaudited Standalone and Consolidated financial results for the Quarter and Half Year ended 30m September, 2021. A copy of the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended 30'h September, 2021 is enclosed herewith. Also attached finanCIaI result highlight (Annexure l)
• . Appointment of Mr. Bhasker Vemban lyer (DIN : 00480341) as an Additional Independent Director with effect from 12m November.2021.

Disclosure pursuant to regulation 30 of SEBl (Listing Obligations and Disclosure Reqwrements) 2015 read with SEBl circular no ClR/CFD/CMD/4/2015 dated 09th September. 2015 is enclosed herewith. (Annexure II)

We would like to further inform you that the Board of Directors had as per the requirement of SEBl circular no. LlST/COMP/14/2018—19 dated June 20. 2018 w.r.t. enforcement of SEBl Orders regarding appointment of Directors by listed companies, verified that the said person is not debarred from holding the office of Director pursuant to any SEBl order.

Re~appointment of Dr. Dinesh S. Patel (DIN :00033273) Executive Vice Chairman of the Company, whose current term will be ending on 13m February, 2022,, whose current term will be ending on 13m February, 2022. The Board has re—appointed him as Executive Vice Chairman of the Company for a further period of 5 years years with effect from 14th February,2022 subject to approval by the shareholders. ( Annexure Ill)

Themis Medicare Limited (7. , 1'

Corporate Office ' 'i 1 12. Udyog Nagar. 8 V Road Contagion i'West'i Miiinbai 4:10 101 il'ili ,L'; Tel. 91422-6760 7080 ' Fax 2 91 22 6700 70m 2874 6621 Hegd. Dttice : Plot No 69A 0 l 0 C Industrial Tsiate, Vapi . 396 195 Guiaiat CIN N0; 0411001969l'L0001590 - Tel 1' Fax No: Regd. 0ft 1060243144] . 2430219 Eimail ' mp TliSfilm]BlilllltitfltiHR." (70t - Website: wwwthiriiisrned'careiirim

During the tenure of his reappointment he will be completing 75 years of age. The Board also approved his continuation as Director and Executive Vice Chairman beyond the age of 75 years subject to the approval of the Shareholders.

1. Re-appointment of Dr.Sachin D. Patel (DIN: 00033353) as Managing Director & CEO of the Company, whose current term will be ending on 13th February, 2022. The Board has re-appointed him as Managing Director & CEO for further period of 5 years with effect from 14th February, 2022 subject to approval by the shareholders. ( Annexure IV)

MUMBA

This may be taken as compliance under the Listing Regulations.

Kindly acknowledge.

Thanking you,

Yours faithfully. For THEMIS MEDICARE LIMITED

Sangameshwar Iver Company Secretary & Compliance Officer*

$\mathcal{O}(10^{-10})$ and

Encl $\frac{2}{3}$ as above

Themis Medicare Limited

Corporate Office: 11/12. Udvog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India Tel.: 91-22-6760 7080 · Fax: 91-22-6760 7070 / 2874 6621 Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat. CIN No.: L24110GJ1969PLC001590 · Tel / Fax No.: Regd. Off.: 0260 2431447 / 2430219 . F.mail · themic@themicmedicare.com . Webcite · www.themicmedicare.com

Annexure-

R. P. Sardar & Co. Chartered Accountants

1. Beuna Vista, Next to ICICI Bank, Holy Cross Road, I. C. Colony, Borivali (West), Mumbai - 400 103. Tel.: +91-22-2893 3556 · Mobile: +91-98212 16687 E-mail: rpsardar@gmail.com

Limited Review Report on Unaudited Ouarterly and Year-to-date Standalone Financial results of the company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) regulation, 2015, as amended ("Listing Regulations").

To The Board of Directors THEMIS MEDICARE LIMITED

• 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of THEMIS MEDICARE LIMITED ("the Company") for the Quarter ended on 30 September, 2021 and year to date results of the period 01 April, 2021 to 30 September, 2021 ("the Statement").
• 1. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
• 1. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies thereon, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R.P. Sardar & Co. Chartered accountants (Firm's Registration No. 109273W) Pinet

Raju P. Sardar (Proprietor) (Membership No. 037845) $UDIN - 21037845AAA$

KDAR

MUMBAI-103 Membership No.

$037845$

$APO20$

Place: Mumbai Date: 12/11/2021

R. P. Sardar & Co. Accountants Chartered

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road. I. C. Colony, Borivali (West), Mumbai - 400 103. Tel.: +91-22-2893 3556 · Mobile: +91-98212 16687 E-mail: rpsardar@gmail.com

Limited Review Report on Unaudited Quarterly and Year-to-date Consolidated Financial results of the company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) regulation, 2015, as amended ("Listing Regulations").

To

à.

The Board of Directors THEMIS MEDICARE LIMITED

• 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of THEMIS MEDICARE LIMITED (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and the total comprehensive income of its associates for the quarter ended September 30, 2021 and year to date results for the period from April 01, 2021 to September 30, 2021 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. ('Listing Regulations')
• 1. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review
• We conducted our review of the Statement in accordance with the Standard on Review $3.$ Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

R.P. Sardar & Co.

Chartered Accountants

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

1. The Statement includes the results of the following entities:

Subsidiaries

• a. Carpo Medical Limited (UK)
• Themis lifestyle Private limited $h$
• Artemis biotech Limited $\overline{c}$ .

Associates

• a. Gujarat Themis Biosys Limited
• b. Long Island Nutritionals Private Limited

Associate (Joint Venture)

• Richter Themis Medicare (India) Private Limited $\overline{a}$
• 1. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed or that it contains any material misstatement.
• We did not review the financial information of 2 Associates $&$ 1 Joint Venture, whose 6. financial information reflect total assets of Rs.25,104.86 Lakhs as at 30 September, 2021 and total revenues of Rs.5.844.39 Lakhs and Rs.11,603.50 Lakhs, total net Profit after tax of Rs.1,574.57 Lakhs and Rs.3,166.95 Lakhs and total comprehensive income of Rs.-0.77 Lakhs and Rs.-1.54 Lakhs for the quarter ended 30 September, 2021 and for the period from 01 April, 2021 to 30 September, 2021, as considered in the consolidated unaudited financial results.
• 1. One subsidiary which is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles, generally accepted in the country and which have been audited by other auditor under generally accepted auditing standards applicable in the country. The Company's

R.P. Sardar & Co.

Chartered Accountants

management has converted the financial statement of such subsidiary located outside India from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affair of such subsidiary located outside India is based on the report of the other auditor and the conversion adjustments prepared by the management of the Company and audited by us.

Our conclusion on the Statement is not modified in respect of the above matter.

For R.P. Sardar & Co. Chartered accountants (Firm's Registration No.-109273W)

Avid

Place: Mumbai Date: 12/11/2021

费

MUMBAI-10. Raju P. Sardar Membership? 037845 (Proprietor) (Membership No. 037845) DACC VDIN-21037845AAAAPN6930

RDAA

THEMIS MEDICARE LTD

CIN NO: L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219. Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2021.

	Statement of Onaddition infancial Results for the guarter and han						(Amount in INR Lakhs)
		STANDALONE
	Particulars	3 monthsended	Preceeding 3monthsended	Corresponding3 monthsended	Year to datefigures forthe currentperiod ended	Year to datefigures forthe previousperiod ended	Year Ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
$\mathbf{1}$	Revenue from Operations	10,739.10	11,250.35	5,489.23	21,989.45	10,338.07	23,066.98
$\overline{2}$	Other Income	21.33	34.93	213.11	56.26	249.01	362.21
3	Total Income $(1 + 2)$	10,760.43	11,285.28	5,702.34	22,045.71	10,587.08	23,429.19
$\overline{4}$	Expenses:
	(a) Cost of materials consumed	3,114.34	2,970.83	1,904.53	6,085.17	3,153.74	6,792.42
	(b) Purchases of stock-in-trade	934.27	838.18	275.30	1,772.45	530.99	1,155.45
	(c) Changes in inventories of finished goods, work-in-progress andstock-in-trade	71.65	342.21	(355.21)	413.86	(168.12)	(126.90)
	(d) Employee benefits expense	1,426.34	1,083.95	953.83	2,510.29	1,970.02	3,998.98
	(e) Finance Costs	205.16	266.91	370.75	472.07	670.21	1,271.21
	(f) Depreciation and amortisation expense	237.51	235.03	203.97	472.54	407.79	854.55
	(g) Other expenses	2,846.33	1,967.67	1,738.88	4,814.00	2,649.69	6,258.65
	Total expenses	8,835.60	7,704.78	5,092.05	16,540.38	9,214.32	20,204.36
5	Profit / (Loss) before exceptional items and tax (3 - 4)	1,924.83	3,580.50	610.29	5,505.33	1,372.76	3,224.83
6	Exceptional items
	Profit / (Loss) before tax (5 - 6)	1,924.83	3,580.50	610.29	5,505.33	1,372.76	3,224.83
8	Tax expense :
	(a) Current Tax	325.00	650.00		975.00
	(b) Deferred Tax	87.67	257.14	41.96	344.81	240.07	562.78
9	Profit / (Loss) for the period (7 - 8)	1,512.16	2,673.36	568.33	4,185.52	1,132.69	2,662.05
10	Other Comprehensive Income:
	(a i) Items that will not be reclassfied to Profit & Loss	(10.64)	(10.64)	(2.79)	(21.28)	(5.58)	(42.56)
	(a ii) Income Tax relating to Items that will not be reclassfied toProfit & Loss	2.68	2.68	0.71	5.36	1.41	10.71
	(b) Items that will be reclassfied to Profit & Loss
	Total Comprehensive Income for the period (9 + 10)	1,504.20	2,665.40	566.25	4,169.60	1,128.52	2,630.20
1112	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	919.95	919.40	918.85	919.95	918.85	918.85
13	Other Equity (Excluding Revaluation Reserve)						14,204.20
14	Earnings per share:
	(a) Basic	16.44	29.08	6.19	45.50	12.33	28.97
	(b) Diluted	16.40	29.03	6.18	45.41	12.32	28.96

THEMIS MEDICARE LTD

CIN NO: L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219. Corporate Office: 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104. Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2021.

							(Amount in INR Lakhs)
		CONSOLIDATED
	Particulars	3 monthsended	Preceeding 3monthsended	Corresponding3 monthsended	Year to datefigures forthe currentperiod ended	Year to datefigures forthe previousperiod ended	Year Ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	10,739.10	11,250.35	5,489.23	21,989.45	10,338.07	23,066.98
$\overline{2}$	Other Income	21.33	34.93	213.11	56.26	249.01	362.21
3	Total Income $(1 + 2)$	10,760.43	11,285.28	5,702.34	22,045.71	10,587.08	23,429.19
					$\chi$
4	Expenses :
	(a) Cost of materials consumed	3,114.34	2,970.83	1,904.53	6,085.17	3,153.74	6,792.42
	(b) Purchases of stock-in-trade	934.27	838.18	275.30	1,772.45	530.99	1,155.45
	(c) Changes in inventories of finished goods, work-in-progress andstock-in-trade	71.65	342.21	(355.21)	413.86	(168.12)	(90.29)
	(d) Employee benefits expense	1,426.34	1,083.95	953.83	2,510.29	1,970.02	3,998.98
	(e) Finance Costs	205.20	266.91	370.75	472.11	670.23	1,271.25
	(f) Depreciation and amortisation expense	237.51	235.03	203.97	472.54	407.79	854.71
	(g) Other expenses	2,846.46	1,967.95	1,741.02	4,814.41	2,652.16	6,261.07
	Total expenses	8,835.77	7,705.06	5,094.19	16,540.83	9,216.81	20,243.59
5	Profit / (Loss) before exceptional items, share of Profit/(Loss) ofassociates and joint venture and tax (3 - 4)	1,924.66	3,580.22	608.15	5,504.88	1,370.27	3,185.60
6	Exceptional items		$\omega$	$\omega$ :	$\omega$	$\overline{\phantom{a}}$
$\overline{7}$	Profit / (Loss) before share of Profit / (Loss) of associates and jointventure and tax (5 - 6)	1,924.66	3,580.22	608.15	5,504.88	1,370.27	3,185.60
8	Add: Share of Profit / (Loss) of associates and a joint venture for theperiod	415.57	446.73	247.26	862.30	458.53	947.47
9	Profit / (Loss) before tax $(7 + 8)$	2,340.23	4,026.95	855.41	6,367.18	1,828.80	4,133.07
10	Tax expense :
	(a) Current Tax	325.00	650.00		975.00
	(b) Deferred Tax	87.67	257.14	41.96	344.81	240.07	562.78
11	Profit / (Loss) for the period (9 - 10)	1,927.56	3,119.81	813.45	5,047.37	1,588.73	3,570.29
	Attributable to:
	Equity holders of the Parent	1,927.57	3,119.81	813.45	5,047.38	1,588.73	3,570.30
	Non - Controlling interests	(0.01)	$\omega$	÷	(0.01)	$\overline{\phantom{a}}$	(0.01)
12	Other Comprehensive Income:
	(a i) Items that will not be reclassfied to Profit & Loss	(10.64)	(10.64)	(2.79)	(21.28)	(5.58)	(42.56)
	(a ii) Income Tax relating to Items that will not be reclassfied toProfit & Loss	2.68	2.68	0.71	5.36	1.41	10.71
	(a iii) Share of Other Comprehensive Income of Associates andJoint Ventures accounted using equity method	(0.18)	(0.18)	(0.00)	(0.36)	0.01	(0.71)
	(b) Items that will be reclassfied to Profit & Loss	(0.89)	1.02	1.34	0.13	7.28	(8.15)
13	Total Comprehensive Income for the period $(11 + 12)$	1,918.53	3,112.69	812.71	5,031.22	1,591.85	3,529.58
	Attributable to:
	Equity holders of the Parent	1,918.54	3,112.69	812.71	5,031.23	1,591.85	3,529.59
	Non - Controlling interests	(0.01)			(0.01)		(0.01)
14	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	919.95	919.40	918.85	919.95	918.85	918.85
15	Other Equity (Excluding Revaluation Reserve)						17,474.63
16	Earnings per share:
	(a) Basic	20.95	33.93	8.85	54.87	17.29	38.86
	(b) Diluted	20.90	33.88	8.85	54.76	17.28	38.84

NOTES:

1 Statement of Assets and Liabilities :

(Amount in INR Lakhs)

		(STANDALONE)	(CONSOLIDATED)
Particulars	As at 30thSeptember,2021	As at 31stMarch, 2021	As at 30thSeptember.2021	As at 31stMarch, 2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
ASSETS
Non-Current Assets
(a) Property, Plant and Equipment	12,858.35	12,974.53	12,858.94	12,975.00
(b) Capital Work-in-Progress	704.07	247.21	704.07	247.21
(c) Right-of-use Assets	162.22	214.37	162.22	214.37
(d) Intangible Assets	109.80	120.72	109.80	120.72
(e) Investments accounted for using the equity method	u,	$\sim$	5,338.14	4,476.21
(f) Financial Assets
(i) Investments	1,098.49	1,097.80	20.34	19.65
(ii) Other Financial Assets	31.13	28.13	31.13	28.13
(g) Other Non-Current Assets	490.43	485.77	490.43	485.77
	15,454.49	15,168.53	19,715.07	18,567.06
Current assets
(a) Inventories	5,800.45	5,849.44	5,800.45	5,849.44
(b) Financial Assets
(i) Trade Receivables	9,458.54	7,796.30	9,423.18	7,760.94
(ii) Cash and Cash Equivalents	1,567.26	1,900.47	1,568.54	1,901.80
(iii) Bank Balances Other than (ii) above	1,000.38	561.55	1,000.38	561.55
(iv) Other Financial Assets	538.71	531.97	538.71	531.97
(c) Other Current Assets	2,307.41	2,032.10	2,216.56	1,941.25
	20,672.75	18,671.83
TOTAL	36,127.24		20,547.82	18,546.95
		33,840.36	40,262.89	37,114.01
EQUITY AND LIABILITIES
Equity
(a) Equity Share capital	919.95
(b) Other Equity	21,471.42	918.85	919.95	918.85
Equity attributable to equity holders of the parent		17,661.40	25,603.48	20,931.83
Non Controlling Interest	22,391.37	18,580.25	26,523.43	21,850.68
Total Equity			(0.07)	(0.06)
	22,391.37	18,580.25	26,523.36	21,850.62
Liabilities
Non Current Liabilities
(a) Financial Liabilities
(inBorrowings)	2,090.25	2,219.70	2,090.25	2,219.70
(ii) Lease Liabilities	81.50	118.25	81.50	118.25
(b) Provisions
(c) Deferred Tax Liabilities (Net)	434.29	94.83	434.29	94.83
	2,606.04	2,432.78	2,606.04	2,432.78
Current Liabilities
(a) Financial Liabilities
(i) Borrowings	4,429.63	6,295.94	4,429.63	6,295.94
(ii) Lease Liabilities	73.96	84.31	73.96	84.31
(iii) Trade Payables
total outstanding dues of micro enterprises and small
	18.06	37.94	18.06	37.94
enterprises
total outstanding dues of creditors other than micro	4,111.09	3,040.26	4,112.03
enterprises and small enterprises
(iv) Other Financial Liabilities	1,972.53	2,238.08	1,973.66
	49.51	981.50	51.10	3,041.252,238.78983.09
	150.05	149.30	150.05
(b) Other Current Liabilities(c) Provisions(d) Current Tax Liabilities (Net)	325.0011,129.83	12,827.33	325.0011,133.49	149.3012,830.61

$\mu$

$\overline{DIC}$ Ò, MUMBAI

2 Statement of Cash Flows:

(Amount in INR Lakhs)

		(STANDALONE)	(CONSOLIDATED)
Particulars	As at 30thSeptember,2021	As at 31stMarch, 2021	As at 30thSeptember,2021	As at 31stMarch, 2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Profit before tax	5,505.33	3,224.83	6,367.18	4,133.07
Adjustments for:				$\mathcal{L}$
Depreciation and amortisation expense	472.54	854.55	472.54	854.71
Loss on sale of property, plant and equipment	3.50	(2.26)	3.50	(2.26)
Changes in fair value of financial instruments at fair valuethrough profit or loss	(0.70)	(1.88)	(0.70)	(1.88)
Dividend and interest income classified as investing cash flows	(13.65)	(234.01)	(13.65)	(234.01)
Finance costs	315.68	1,096.57	315.68	1,096.57
Share of (profit) Loss from joint ventures and associates	÷.		(861.94)	(946, 75)
Change in operating assets and liabilities:
(Increase)/Decrease in trade receivables	(1,662.24)	2,487.49	(1,662.24)	2,487.49
(Increase)/Decrease in inventories	48.99	(425.16)	48.99	(388.55)
Increase/(decrease) in trade payables	1,050.95	110.23	1,050.90	110.88
(Increase)/Decrease in other financial assets	(9.74)	(43.99)	(9.74)	(43.99)
(Increase)/decrease in other assets	(275.31)	(626.00)	(275.31)	(616.29)
Increase/(decrease) in provisions	(20.52)	(30.52)	(20.52)	(30.52)
(Increase)/Decrease in Other bank balance	(438.84)	(366.22)	(438.84)	(366.22)
Increase/(decrease) in other financial liabilties	(265.55)	(1,307.43)	(265.12)	(1,316.29)
Increase/(decrease) in other liabilities	(931.98)	953.62	(932.32)	953.85
Cash generated from operations	3,778.46	5,689.82	3,778.41	5,689.81
Less: (Income taxes paid)/ refund received (Net)	(654.66)	7.70	(654.66)	7.70
Net cash inflow from operating activities	3,123.80	5,697.52	3,123.75	5,697.51
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for property, plant and equipment	(765.91)	(1,803.88)	(765.91)	(1,803.88)
Proceeds from sale of property, plant and equipment	12.26	4.75	12.26	4.75
Dividends received		192.80		192.80
Interest received	13.65	41.21	13.65	41.21
Net cash outflow from investing activities	(740.00)	(1, 565.12)	(740.00)	(1, 565.12)
CASH FLOWS FROM FINANCING ACTIVITIES:				$\tilde{\mathcal{X}}$
Proceeds from issues of equity shares	37.11	1.55	37.11	1.55
Receipts / (Repayment) of Curent borrowings	(1,866.31)	(1, 365.39)	(1,866.31)	(1,365.39)
Receipts / (Repayment) of non Curent borrowings	(129.45)	122.52	(129.45)	122.52
Repayment of lease liabilities	(47.10)	(66.07)	(47.10)	(66.07)
Interest paid	(315.68)	(1,096.57)	(315.68)	(1,096.57)
Dividends paid	(395.58)	(160.79)	(395.58)	(160.79)
Net cash inflow (outflow) from financing activities	(2,717.01)	(2, 564.74)	(2,717.01)	(2, 564.74)
Net increase (decrease) in cash and cash equivalents	(333.21)	1,567.66	(333.26)	1,567.65
Cash and Cash Equivalents at the beginning of the financial year	1,900.47	332.81	1,901.80	334.15
Cash and Cash Equivalents at end of the year	1,567.26	1,900.47	1,568.54	1,901.80
Reconciliation of cash and cash equivalents as per the cash
flow statement:
Cash and cash equivalents as per above comprise of the
following:
Balances with banks
- On current accounts	1,548.16	1,896.22	1,549.19	1,897.294.51
Cash on hand	19.10	4.25	19.35
Balances per statement of cash flows	1,567.26	1,900.47	1,568.54	1,901.80

$\begin{matrix} 1 \end{matrix}$

$EDCA$ $EMIS$ MUMBAI

• 1. The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at Its meeting held on November 12, 2021. 3)TheaboveUnauditedFinancialResultswerereviewedbytheAuditCommitteeandhavebeenconsideredandapprovedbytheBoardofDirectorsatItsmeetingheldonNovember12,2021.
• 1. The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016. 4)TheabovefinancialresultshavebeenpreparedinaccordancewithIndianAccountingStandards(IndAS)asprescribedundersection133oftheCompaniesAct,2013readwithRule3oftheCompanies(IndianAccountingStandards)Rules,2015andtheCompanies(IndianAccountingStandards)Rules,2016.
• S) The paid~up equity share capital stands increased to 3 919,95 lal<hs(91,99,5/10 equity shares of i 10 each) upon allotment oi 5.578 equity shares of i 10 each pursuant to "£805 2012" during the quarter ended 30th September, 2021, S)Thepaid~upequitysharecapitalstandsincreasedto3919,95lal<hs(91,99,5/10equitysharesofi10each)uponallotmentoi5.578equitysharesofi10eachpursuantto"£8052012"duringthequarterended30thSeptember,2021,
• 1. The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable semnents as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments". 6)TheCompanyoperatesinasingleBusinesssegmenti.ePharmaceuticalsandhencedoesnothaveanyreportablesemnentsasperIndianAccountingStandard(IndAS)108-"OperatingSegments".
• 1. The Company continues to closely monitor the impact of the COVIDJO pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners The management has exercised due care, in concluding on significant accounting iudgements and estimates, interialia, recoverability oi receivables, assessment for irripairment oi inyestments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter and half year ended 30th September, 2021. 7)TheCompanycontinuestocloselymonitortheimpactoftheCOVIDJOpandemiconallaspectsofitsbusiness,includinghowithasimpactedandwillimpactitscustomers,employees,vendorsandbusinesspartnersThemanagementhasexercisedduecare,inconcludingonsignificantaccountingiudgementsandestimates,interialia,recoverabilityoireceivables,assessmentforirripairmentoiinyestments,intangibleassets,inventory,basedontheinformationavailabletodate,bothinternalandexternal,whilepreparingtheCompany'sfinancialresultsforthequarterandhalfyearended30thSeptember,2021.Date:12thNovember,2021(DINNo.00033353)section133oftheCompaniesAct,2013readwithRule3oftheCompanies(IndianAccountingStandards)Rules,2015andtheCompanies(IndianAccountingStandards)Rules,2016.S)Thepaid~upequitysharecapitalstandsincreasedto3919,95lal<hs(91,99,5/10equitysharesofi10each)uponallotmentoi5.578equitysharesofi10eachpursuantto"£8052012"duringthequarterended30thSeptember,2021,6)TheCompanyoperatesinasingleBusinesssegmenti.ePharmaceuticalsandhencedoesnothaveanyreportablesemnentsasperIndianAccountingStandard(IndAS)108-"OperatingSegments".7)TheCompanycontinuestocloselymonitortheimpactoftheCOVIDJOpandemiconallaspectsofitsbusiness,includinghowithasimpactedandwillimpactitscustomers,employees,vendorsandbusinesspartnersThemanagementhasexercisedduecare,inconcludingonsignificantaccountingiudgementsandestimates,interialia,recoverabilityoireceivables,assessmentforirripairmentoiinyestments,intangibleassets,inventory,basedontheinformationavailabletodate,bothinternalandexternal,whilepreparingtheCompany'sfinancialresultsforthequarterandhalfyearended30thSeptember,2021.8)i'igureslorthecorrespondingpreviousyear/periodhavebeenregrouped/rearranged,wherevernecessary,tomakethemPlace:Mumbai(ManagingDirector&CEO)Date:12thNovember,2021(DINNo.00033353)
• 1. i'igures lor the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable. 8)i'igureslorthecorrespondingpreviousyear/periodhavebeenregrouped/rearranged,wherevernecessary,tomakethem

By Order of the Board For THEMIS MEDICARE LTD

Dr. SACHIN PATEL

Place : Mumbai (Managing Director & CEO) Date :12th November, 2021 (DIN No. 00033353) Place:Mumbai(ManagingDirector&CEO)

Themis Medicare Limited EM IS Themis Medicare Limited

Financial Highlights - Consolidated Financial Highlights - Consolidated

H1 FY22 Revenue at Rs. 220 crore H1 FY22 Revenue at Rs. 220 crore

H1 FY22 EBITDA at Rs. 64 crore H1 FY22 EBITDA at Rs. 64 crore

H1 FY22 EBIDTA Margin at 29 % H1 FY22 EBIDTA Margin at 29 %

H1 FY22 PAT at Rs. 50crore H1 FY22 PAT at Rs. 50crore

Continued Focus on Complex Generics and Injectables driving performance Continued Focus on Complex Generics and lnjectables driving performance

Key Financials (Rs. Crore): - Kev Financials (Rs. Crore): -

ParticularsParticulars	Q2 FY22Q2FY22	Q2 FY21Q2FY21	Y-o-YY-o-Y	Q1 FY22Q1FY22	H1 FY22H1FY22	H1 FY21H1FY21	Y-o-Y
Revenue from OperationsRevenuefromOperations	107107	5555	95 %%95	113113	220220	103103	114 %114%
EBIDTAEBIDTA	2424	1010	140 %140%	404O	6464	2222	191 %191%
EBITDA%EBITDA%	22 %%22	18 %18%	400 bps400bps	35 %35%	29 %29%	21 %21%	800 bps800bps
PATPAT	1919	88	138 %138%	3131	5050	1616	213 %213%
Basic EPS (Rs.)(Rs.)BasicEPS	20.9520.95	8.858.85	137 %137%	33.9333.93	54.8754.87	17.2917.29	217 %217%

Performance Highlights: - Performance Highlights: -

For the quarter ended September 30th, 2021: For the quarter ended September 30th, 2021:

• Revenue from Operations stood at Rs. 107crore in Q2 FY22, as against Rs. 55crore in Q2 FY21, growth of over 95 % mainly on account of higher volumes and better product mix. 0 Revenue from Operations stood at Rs. 107crore in Q2 FY22, as against Rs. 55crore in Q2 FY21, growth of over 95 % mainly on account of higher volumes and better product mix.

• EBITDA for the quarter was Rs. 24crore as against Rs. 10crore in Q2 FY21, increase of 140 % - EBITDA Margin stood at 22 % as against 18 % for respective quarters – increase being on account of greater efficiencies and higher contribution from Injectables business in absolute terms. 0 EBITDA for the quarter was Rs. 24crore as against Rs. 10crore in Q2 FY21, increase of 140 % — EBITDA Margin stood at 22 % as against 18 % for respective quarters — increase being on account of greater efficiencies and higher contribution from lnjectables business in absolute terms.

• Q2 FY22 Profit stood at Rs. 19 crore as against profit of Rs. 8crore in Q2 FY21, increase of 138 %. 0 Q2 FY22 Profit stood at Rs. 19 crore as against profit of Rs. 8crore in Q2 FY21, increase of 138 %.

For the half-year ended September 30th, 2021: For the half-year ended September 30th, 2021:

• Revenue from Operations stood at Rs. 220 crore in H1 FY22, as against Rs. 103 crore in H1 FY21, growth of 114 % mainly on account of higher contribution from Injectablesexports along with a better product mix. 0 Revenue from Operations stood at Rs. 220 crore in H1 FY22, as against Rs. 103 crore in H1 FY21, growth of 114 % mainly on account of higher contribution from Injectablesexports along with a better product mix.

• EBITDA stood at Rs. 64crore as against Rs. 22crore in H1 FY21, increase of 191 % - EBITDA Margin stood at 29 % as against 21 % for respective periods – incremental capacity utilization and higher contribution from Injectables business led to better profitability in absolute terms. 0 EBITDA stood at Rs. 64crore as against Rs. 22crore in H1 FY21, increase of 191 % — EBITDA Margin stood at 29 % as against 21 % forrespective periods — incremental capacity utilization and higher contribution from Injectables business led to better profitability in absolute terms.

• H1 FY22 Profit stood at Rs. 50crore as against profit of Rs. 16crore in H1 FY21, increase of 213%. 0 H1 FY22 Profit stood at Rs. 50crore as against profit of Rs. 16crore in H1 FY21, increase of 213%.

• Exports sales for H1 FY22 stood at 47 % of total revenue as against 36 % in H1 FY21. 0 Exports sales for H1 FY22 stood at 47 % of total revenue as against 36 % inH1 FY21.

ANNEXURE II

Disclosures pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Reduirements1 2015 (673001101 SEBI c1 rcuiar no CIR/CFD/CMD/4/2015 dated 09"" September 2015

Mr.'-	Bhasker yer(DlN:VembanReasonfor		00480341)727.2,,,
	change7' 'APPOIMm		MrBhaskerVembanIyeriDIN* 00480341;appomtedat:as
2	ointmenti.Date		AdditionalIndependentDirector12
	of App		November202177777777
3:	Brief Profile	'	BhaskerisstrategicbusinessleaderwrthfourdecadesaoverofexperienceinthepharmaceuticalandhealthcareindustryspanningcountrymanagementgloballeadershipandBoardDirectorshiproles
	i'	Ii	HecurrentlyworksOperatingPartnerat.AdventasaninternationalglobalPrivateEquityfirm.HeisalsoaanOperatingAdVisorforHealthcare-focussedPrivateEquityafirm.QuadriaCapitalHeistheBoardsof BharatSerumandonVaccines,RAChem.RPGLifeSciencesandZCLChemicalsIndependentDirectoras
		i	0PriorjOIningAdventtoOperatingPartner,BhaskerasanwasaCorporateOfficerwithAbbottthelargestMNCHealthcare,inIndiawiththreeManagingDirectorsandallcompanyfunctionalHeadsofthePharmaceuticalBusmessreportingtohim.HeresponSibIeforturnoverupwardsUSDatwasa1bi lionand12000employees.
	I	11I	. HehasheldgloballeadershippositionswrthWockhardtinIndiaandAstraZenecainASIaPacrficbasedinSingaporeandcountrymanagementpOSitionsinAstraZeneca.NicholasPiramalIndiaLtd,ICIPharmaceuticalsandseniorIflirolesGlaxoIndiaLtd.
		1	. BhaskerhasBachelor'sdegreeinScienceandMastersinaMarketingManagementfromJamnalaiBajajInstituteofManagementStudies.
411,,	'DisclosureofIrelationshipbetween5(idirectorsofncaseappointmentofaarm	11''	NotApplicable

For Themis Medicare Limited.

'_,_

S,

D

Sangameshwar Iyer Company Secretary 8- Compliance Officer

Themis Medicare Limited

Corporate Ottice : 1'12.UdyogNagar, S V Roar: tlt'gdtlil (Westi MIIITlIlal . 400 '04 Ild'it Tel: 1-2? 6760 7080 ' Fax: 91 22- 6760 70 2874 6621 Regd Office:9Plot No 69-71 0101 IIdLISil'IdILSIEIIBOVEIUI3961195. GUiarat DIN No.: I2411001969PLCOO1590- Tel,l Fax No: Hegd DH; 0260 2431447 2430219 F.mni| - thr nicrn'ithnmiL'madir'um rum u \Alnhciln - minim1hni11icmpr'icarit1'0'11

ANNEXURE III

Disclosures pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 read with SEBI circular no CIR/CFD/CMD/4/2015 dated 09th September, 2015.

	$D1.$ Diffesh O. Fater (DIN . 00033213)
1.	Reason for change /		Re-appointment of Dr. Dinesh S. Patel, Executive Vice Chairman
	Appointment		of the Company, whose current term will be ending on 13 th
			February, 2022. The Board has re-appointed him as Executive
			Vice Chairman of the Company for a further period of 5 years
			subject to approval by the shareholders.
			During the tenure of his reappointment he will be completing 75
			years of age. The Board also approved his continuation as
			Director and Executive Vice Chairman beyond the age of 75 years
			subject to the approval of the Shareholders.
2.	Date of Appointment		The Board at its meeting held on 12 th November, 2021 has
			Reappointed Dr, Dinesh S Patel for a further period of 5 years
			with effect from 14 th February, 2022
3.	Brief Profile		Dr. Dinesh Patel is the Executive Vice-Chairman on the Board
			of Directors and formerly was Managing Director & CEO.
			Dr. Patel holds a Doctorate in Medicinal Chemistry. He is a
			Fellow of the Royal Society of Chemistry, London, U.K. Dr.
			Dinesh Patel has also been associated with many Academic
			Institutes.
			Dr. Patel joined the business in the year 1973. His area of$\bullet$
			expertise are research, biotechnology, banking and business
			operations.
	觑
4.	Disclosureof	$\mathcal{L}_{\mathcal{A}}$	Dr Dinesh Patel is a relative of the following Directors
	relationships
	between directors (in		1. Dr. Sachin D Patel - Managing Director & CEO
	case of appointment		2. Mrs. Jayshree D Patel - Whole time Director
	of a director).
			3. Mrs, Reena S Patel - Alternate Director

Dr. Dinesh S. Patel (DIN : 00033273)

For Themis Medicare Limited.

MUMBA Sangameshwar Iver Company Secretary & Compliance Officer

Themis Medicare Limited

$DIC$

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India Tel.: 91-22-6760 7080 · Fax: 91-22-6760 7070 / 2874 6621 Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat. CIN No.: L24110GJ1969PLC001590 · Tel / Fax No.: Regd. Off. : 0260 2431447 / 2430219 . F.mail · themis@themismedicare.com . Website · www.themismedicare.com

ANNEXURE IV

Disclosuies pursuant to regulation 30 of SEBli Listing Obiigations and Disclosure Requirementsr 2015 read With SEBI circular no ClRi'ICFD I'iCMD 4/2015 dated 09 September ,230

Dr Sachin D Patel (DIN: 00033353)

1	I .changeforReason'Appointmentl		CEDDirector&ManagingPatelSachinDofDrappOIntmentRe—33endingbeWilloncurrenttermwhoseCompanytherotManagingre——appomtedhimBoardhasasThe2022Februaryperiodof5furtheryearsforCompanyoftheCEOaDirector&shareholderstheapprovalbysubjectto
2	Appointmieint' DateBt	:7''	hasRe,2021November32heldmeetingBoardat itsTheonwithperiodof 5furtheryearsPatelto.ISachinDappomtedDra2022February14theffectfrom
33	N3PfirOfile' Brief	Ii	DirectorManagingDeputyformerlythePatelSachin0Dr.was2004boardtheDevelopmentsrnceBusrnessonandDirectorDirectorManagingre—designatedbeenhasasPatelSachinDr.201.714,FebruaryCEOsince&Christ'sfromChemistryBiologicalinDoctorateholdsHe0aUKof CambridgeUniverSItyCollege,
4	ofI Disclosurerelationships(Indirectorsbetweenappomtmentof31casedirector).77ofa	V,	Directorsof thefollowrngrelativePatelisSachinD: Dral/ C€ChairmanExecutivePatelDineshSDr.1.-timeDirectorWholePatelDMrs.Jaysnree2.—:DirectorAlternatePatel39.903S73.Mrs.—

For Themis Medicare Limited.

, ( '-,._

Sangameshwar lyer Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Ollice: l2 UdyogNagatS ' Road CommonriWi:sti "iMind: 4:30 '0~' India Tel 22-6760 7080- Fax: 9i 22 6:00 0 0 2871mm Regd. Ollice . HUT. NI; 69 A 0 I ,it? industrial tstdte Vapi 3&93' E 5 Guaral CIN N0 : t24': tOtlJ1969PL000'590 - Tel f Fax No.: Regd.0f1. : 0260 24344? 24302"? F-mail ' i'lfl'illWiLtI'EmISlllliflll'lAlt? Itnrii - Website: WWW"it"i'lS'llell0:3"?[2033